Evidence map›Paper›PMID 37171631›Full record

ReviewEJNMMI research2023

Visualizing GABA transporters in vivo: an overview of reported radioligands and future directions.

Niels Knippenberg, Matthias Bauwens, Olaf Schijns, Govert Hoogland, Alexandru Florea, Kim Rijkers, Thomas J Cleij, Kasper Eersels, Bart van Grinsven, Hanne Diliën

Open access · goldAbstract readReview
In one paragraph

Review in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  2. Review
  3. Synthesis and Evaluation of BenzylicACS chemical neuroscience · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Niels KnippenbergSensor Engineering Department, Faculty of Science and Engineering, Maastricht University, 6200 MD, Maastricht, The Netherlands. niels.knippenberg@maastrichtuniversity.nl.ORCID http://orcid.org/0000-0002-5124-4828
Matthias BauwensDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.ORCID https://orcid.org/0000-0002-8176-1084
Olaf SchijnsDepartment of Neurosurgery, Maastricht University Medical Centre+ (MUMC+), 6229 HX, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0001-8295-0728
Govert HooglandDepartment of Neurosurgery, Maastricht University Medical Centre+ (MUMC+), 6229 HX, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0001-8649-9890
Alexandru FloreaDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.ORCID https://orcid.org/0000-0002-2076-0723
Kim RijkersDepartment of Neurosurgery, Maastricht University Medical Centre+ (MUMC+), 6229 HX, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-3348-158X
Thomas J CleijSensor Engineering Department, Faculty of Science and Engineering, Maastricht University, 6200 MD, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0003-0172-9330
Kasper EerselsSensor Engineering Department, Faculty of Science and Engineering, Maastricht University, 6200 MD, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-0214-1320
Bart van GrinsvenSensor Engineering Department, Faculty of Science and Engineering, Maastricht University, 6200 MD, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-6939-0866
Hanne DiliënSensor Engineering Department, Faculty of Science and Engineering, Maastricht University, 6200 MD, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0001-5409-3941
Maastricht University · NLMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By clearing GABA from the synaptic cleft, GABA transporters (GATs) play an essential role in inhibitory neurotransmission. Consequently, in vivo visualization of GATs can be a valuable diagnostic tool and biomarker for various psychiatric and neurological disorders. Not surprisingly, in recent years several research attempts to develop a radioligand have been conducted, but so far none have led to suitable radioligands that allow imaging of GATs. Here, we provide an overview of the radioligands that were developed with a focus on GAT1, since this is the most abundant transporter and most of the research concerns this GAT subtype. Initially, we focus on the field of GAT1 inhibitors, after which we discuss the development of GAT1 radioligands based on these inhibitors. We hypothesize that the radioligands developed so far have been unsuccessful due to the zwitterionic nature of their nipecotic acid moiety. To overcome this problem, the use of non-classical GAT inhibitors as basis for GAT1 radioligands or the use of carboxylic acid bioisosteres may be considered. As the latter structural modification has already been used in the field of GAT1 inhibitors, this option seems particularly viable and could lead to the development of more successful GAT1 radioligands in the future.

Indexed as

GABAGABA transporterGAT inhibitorGAT radioligandPET imaging

Identifiers

PMID37171631
PMCPMC10182260
OpenAlexW4376225414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.